

WEST PHARMACEUTICAL SERVICES INC
Form 8-K
June 06, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – June 6, 2011

WEST PHARMACEUTICAL
SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction
of Incorporation)

1-8036
(Commission File
Number)

23-1210010
(IRS Employer
Identification No.)

101 Gordon Drive, PO Box
645, Lionville, PA
(Address of principal
executive offices)

19341-0645
(Zip Code)

Registrant's telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On June 6, 2011, our management will present at the Jefferies 2011 Healthcare Conference in New York, New York at 4:00 PM ET. A copy of the presentation materials from the conference will be available for 30 days through the Investors link at the Company's website, <http://www.westpharma.com>, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| | |
|-----------------|---|
| Exhibit 99.1 | West Pharmaceutical Services, Inc. Overview (Investor Presentation). |
|-----------------|---|

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST
PHARMACEUTICAL
SERVICES, INC.

/s/ John R. Gailey III
John R. Gailey III,
Vice President, General
Counsel and Secretary

June 6, 2011

3

EXHIBIT INDEX

| Exhibit No. | Description |
|-------------|--|
| 99.1 | West Pharmaceutical Services, Inc. Overview (Investor Presentation). |

: 0pt; MARGIN-RIGHT: 0pt">

13. Approval of the activities of the Board of Directors, Statutory Auditors, Secretary and Assistant Secretary during the year ended December 31, 2011, and release from any liability they might have incurred in the due execution of their position.
14. Ratification of Mr. Fernando Chico Pardo as President of the Board of Directors.
15. Ratification of all other members and alternate members of the Board of Directors. Mr. Rafael Robles Miaja and Ms. Ana María Poblano Chanona were ratified as non-member Secretary and Assistant Secretary, respectively, to the Board of Directors.
16. Ratification of Mr. Ricardo Guajardo Touché as President of the Audit Committee.
17. Ratification of Mr. Fernando Chico Pardo and Mr. Roberto Servitje Sendra and the appointment of Mr. José Antonio Pérez Anton in replacement of Mr. Rasmus Christiansen, as members of the Nominations and Compensation Committee.
18. Approval of the proposal made by the Nomination and Compensation Committee to pay the following compensation to the members of the management bodies of the Company:
 - Each member of the Board of Directors will receive Ps.50,000.00 (Fifty thousand pesos 00/100, Mexican currency), plus travel expenses, if any, per meeting attended.
 - Each member of the Nominations and Compensations Committee will receive Ps.50,000.00 (Fifty thousand pesos 00/100, Mexican currency), plus travel expenses, if any, per meeting attended.
 - Each member of the Audit Committee will receive Ps.70,000.00 (Seventy thousand pesos 00/100, Mexican currency), plus travel expenses, if any, per meeting attended.
 - Each member of the Operations Committee will receive, Ps.50,000.00 (Fifty thousand pesos 00/100, Mexican currency), plus travel expenses, if any, per meeting attended.
 - Each member of the Acquisitions and Agreements Committee will receive Ps.15,000.00 (Fifteen thousand pesos 00/100, Mexican currency), plus travel expenses, if any, per meeting attended.
19. Special Delegates of the General Annual Ordinary Shareholders' Meeting were appointed to appear before Notary Public to legalize the minutes of this meeting and undertake any other action necessary to formalize and give effect to the resolutions undertaken at this meeting.

About ASUR:

Grupo Aeroportuario del Sureste, S.A.B. de C.V. (ASUR) is a Mexican airport operator with concessions to operate, maintain and develop the airports of Cancun, Merida, Cozumel, Villahermosa, Oaxaca, Veracruz, Huatulco, Tapachula and Minatitlan in the southeast of Mexico. The Company is listed both on the Mexican Bolsa, where it trades under the symbol ASUR, and on the NYSE in the U.S., where it trades under the symbol ASR. One ADS represents ten (10) series B shares.

- END -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Grupo Aeroportuario del Sureste, S.A.B. de C.V.

By: /s/ ADOLFO CASTRO RIVAS
Adolfo Castro Rivas
Chief Executive Officer

Date: April 27, 2012